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Abstract  Objective: To determine the role of protein-with-molecular-weight-53 (p53), 
burkit cell lymphoma 2 (Bcl2),  Fas ligand (FasL) mRNA, and vascular cell adhesion 
molecule 1 (VCAM-1), known as the apoptosis-related molecular pathway, in 
preeclamptic patients. 
 
 Methods: Observation on the correlation between the mRNA levels of p53, 
Bcl2 and FasL and VCAM-1 in 31 subjects at 28-42 weeks gestational age was 
performed in this study using the real time reverse transcriptase-polymerase 
chain reaction (RT-PCR).
 
 Results: The results showed that p53 mRNA increased (>1.2350 ng/μL) in the 
preeclampsia group compared to the normal pregnancy group (p=0.010), 
Bcl2 mRNA was lower (≤0.9271 ng/μL) in the preeclampsia group than the 
control group (p=0.041). There was also a tendency of increased FasL mRNA 
expression (>0.5509 ng/μL) in the preeclampsia group compared to the normal 
pregnancy group (p=0.300). The level of VCAM-1 elevated (>890.08 ng/mL) in 
the preeclampsia group compared to the normal pregnancy group (p=0.001). 
In preeclampsia, the correlation between the Bcl2/p53 ratio and VCAM-1 was 
r=0.541 (p=0.002), whereas the correlation in normal pregnancy was r=0.099 
(p=0.595). 
 
 Conclusions: There are correlations between the mRNA expression levels of p53 
and Bcl2 as an intrinsic pathway of apoptosis along with the VCAM-1 levels in the 
incidence of preeclampsia. However, no correlation is found between FasL mRNA 
expression and the incidence of preeclampsia. 
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Introduction
Preeclampsia in pregnancy is characterized 
by blood pressure of ≥140/90 mmHg in two or 
more measurements which is accompanied by 
proteinuria (30 mg/dL) in two separate tests 
with a nominal measurement scale. There are 
three stages involved in the pathogenesis of 
preeclampsia: abnormal vascular remodeling of 
placenta, placental ischemia, and endothelial 
cell dysfunction.1 Some previous studies have 
hypothesized that the causes of preeclampsia 
originally involve genetic, immunological, and 
other factors resulting in a failure in trophoblast 
proliferation and invasion. These factors lead 
to abnormal placental vascular remodeling and 
endothelial dysfunction, causing the syndrome 
of preeclampsia.
Protein-with molecular weight-53, or p53, 
protects cells against the deoxyribonucleic acid 
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(DNA) damage.2 DNA damage and hypoxia, which 
increases the phosphorylation of p53, occur 
when metabolic processes enhance the role 
of p53 and decrease murine double minute-2 
protein (MDM-2) that will ultimately enhance 
the role of p53 in apoptosis.2–4 However, the 
biosynthetic mechanisms associated with p53 
and apoptosis in pregnancy are not known.2,5
In the intrinsic pathway of apoptosis, the 
mitochondrial genes are primarily regulated by 
burkit cell lymphoma 2 (Bcl2). Tissue samples 
from patients with preeclampsia have shown 
that the expression of the antiapoptotic protein 
Bcl2 is lower than that of patients with normal 
pregnancy. Increased apoptotic activity in the 
placental bed of preeclampsia patients inhibits 
trophoblast invasion into the spiral artery.6
The ligand receptor pathway, or the extrinsic 
pathway, is mediated by cytokines such as 
the tumor necrotic factor alpha (TNFα) and 
Fas ligand (FasL). FasL/Fas plays an important 
role in protecting the fetus from the maternal 
immune system. In mouse experiments, FasL 
played a role to prevent changes in immune cell 
activation between the maternal-fetal surface. 
This showed a decreased expression of FasL on 
the surface of decidual leukocyte infiltration and 
enhanced placental fetal death.6,7
The number of markers indicating endothelial 
dysfunction increase in the blood or urine of 
preeclamptic women. Most of these markers, 
including the vascular cell adhesion molecule 1 
(VCAM-1) and cellular fibronectin, increase during 
several weeks of pregnancy. Placental ischemia 
occurs due to hypoxia, which is presumed to be 
related to the vascular endothelial damage. This 
condition is characterized by increased levels of 
VCAM-1. Increased levels of VCAM-1 improve the 
regulation of the apoptotic caspase cascade. The 
apoptosis that occurs in preeclampsia may occur 
through the intrinsic and extrinsic pathways. The 
role of p53, Bcl2, and FasL messenger ribonucleic 
acid (mRNA) in apoptosis in preeclampsia and 
the uncertainty in which apoptotic pathway 
Table 1 Characteristic of Research Subjects
Variable
Group Significance
Preeclampsia (n=31) Control (n=31) X2/t p Value
Maternal age (yrs.) 0.000 1.000*)
<20 3 3
20–34 21 21
≥35 7 7
Mean 29.29 (7.98) 29.61 (7.40)
Median 18–45 18–44
Gestational age (wks.) 1.409 0.600*)
28–32 1 0
33–37 8 8
38–42 22 23
Mean 37.87 (1.56) 38.23 (0.88)
Median 31–40 37–40
Parity 0.862 0.654*)
0–1 17 17
2–3 10 12
≥ 4 4 2
BMI (kg/m2) 0.595 0.554**)
Mean 22.77 (2.93) 22.27 (3.66)
Median 15–31 18–29
BMI, body mass index; Statistical test *)Chi-square and **)Independent t
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used have prompted further studies. This study 
aimed to determine the role of p53, Bcl2, and 
FasL mRNA and VCAM-1 in preeclampsia.
Methods
Research Subjects
Pregnant women who visited Dr. Hasan Sadikin 
General Hospital, as well as its teaching hospital 
network (Cibabat Hospital and Astana Anyar 
Maternity Hospital) at 28–42 weeks gestational 
age and who were diagnosed with preeclampsia 
(according to the protocol of the Division of 
Feto-maternal Department of Obstetrics and 
Gynecology, Dr. Hasan Sadikin General Hospital, 
Faculty of Medicine, Universitas Padjadjaran, 
Bandung, Indonesia, 2008) served as the case 
group. To comply with the approval from the 
Ethical Committee of Dr. Hasan Sadikin General 
Hospital, informed consent was obtained from 
every single participant in this study. Statistical 
calculations were obtained from a sample size of 
31 patients for both the case and control groups 
from July 2009–April 2010.
The specimens were taken from the placental 
tissue, immediately after the placenta was born. 
Using tweezers and a scalpel, the placental 
tissue was cut approximately 2x2 cm in size and 
put in a sterile tube and received label for the 
RNA expression inspection: p53, Bcl2 and FasL in 
real time-polymerase chain reaction (PCR). The 
placental specimens were immediately frozen in 
liquid nitrogen, then stored in the freezer with a 
temperature of -80 °C until it was used. 
Clinical examination
The physical examination performed in this study 
included the general condition, weight, height, 
as well as a heart and lung examination. Systolic 
and diastolic blood pressure were also measured 
after the patient rested for 15 minutes on her left 
side. The blood pressure was the average of two 
examinations performed at 5-minute intervals.
Determination of VCAM-1 levels
The levels of VCAM-1 protein were determined 
in duplicate experiments by using the enzyme-
linked immunosorbent assay (ELISA) with  the 
human VCAM-1 immunoassay kit (Quantikine) in 
Table 2 Relationship between High-Low Expression of mRNA; p53; Bcl2 and FasL and the Level of 
VCAM-1 in Preeclampsia
Variable
Group Significance
Preeclampsia (=31) Control (n=31) X2 p Value OR (95% CI)
p53 (ng/µL)
Mean 1.18 (0.32) 1.08 (0.17)
> 1.2350 13 4 6.565   0.000 4.87 (1.37–17.35)
≤ 1.2350 18 27
Bcl2 (ng/µL)
Mean 0.84 (0.18) 0.95 (0.20)      
≤ 0.9271 18 10 4.168 0.041 2.91 (0.92–9.43)
> 0.9271 13 21   
FasL (ng/µL)
Mean 0.69 (0.28) 0.64 (0.32)     
> 0.5509 21 16 1.072 0.300 0.51 (0.18–1.42)
≤ 0.5509 10 15
VCAM-1 (ng/mL)
Mean 1077,63 (413.88) 823.99 (271.48)
> 890.08 23 10 10.949 0.001 6.04 (2.01–18.17)
≤ 890.08 8 21
Statistical, Chi-square test; Determination cut-off for p53, Bcl2, FasL and VCAM-1 based on Receiver Operating Characteristics 
Curve (ROC)
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Table 3 Multivariate Analysis of Risk Factors Relationship  mRNA Expression; p53 and Bcl2 and VCAM-
1 Levels with the Incidence of Preeclampsia Based on Multiple Logistic Regression Analysis
Variable Coefficient B SE p Value OR (95% CI)
p53 (ng/µL) 2.572 1.010 0.011 13.09 (1.81–94.70)
Bcl2 (ng/µL) 1.363 0.749 0.069 3.91 (0.90–16.98)
VCAM-1 (ng/mL) 2.820 0.809 < 0.001 16.77 (3.44–81.82)
Constant -2.646
Accuracy of the Model = 74.2%
Table 4 The Correlation between mRNA Expression; p53 and Bcl2 with VCAM-1 Levels in Preeclampsia 
and Normal Pregnancy
Correlation
Group
Preeclampsia (n=31) Control (n=31)
r p Value r p Value
p53 with VCAM-1 -0.490 0.005 -0.415 0.020
Bcl2 with VCAM-1 -0.093 0.619 -0.201 0.278
Ratio Bcl2/p53 with VCAM-1 0.541 0.002 0.099 0.595
Accuracy of the Model = 74.2%
accordance with the manufacturer’s instructions 
(R & D Systems Inc., Minneapolis, MN). The ELISA 
kit is based on a solid phase sandwich ELISA that 
consists of anti-VCAM-1 polyclonal antibody and 
perioxidase conjugated anti-VCAM-1 polyclonal 
antibody. The concentration of VCAM-1  in each 
preparation was determined using the standard 
curve available.
RNA isolation and cDNA synthesis
Total RNA was extracted from fresh frozen 
sections with RNeasy Mini kit (Qiagen, Hilden, 
Germany) in accordance with the instructions 
from the manufacture. The isolated RNA quantity 
was measured by a ND-1000 spectrophotometer 
(NanoDrop Tech., Wilmington, Delaware).  The 
template cDNA was synthesized from 13.5 
μg of total RNA using the Omniscript Reverse 
Transcriptase kit (Qiagen), random primer 
(hexadeoxyribonucleotide mixture, Takara, 
Shiga, Japan), and ribonuclease inhibitor (Porcine 
liver, Takara). Total RNA was reverse transcribed 
with 4 U of Omniscript reverse transcriptase in 
20 μL reaction volume (60 minutes at 37 °C, 5 
minutes at 93 °C, and finally put on ice). Resulting 
cDNA samples were then stored at -30 °C until 
the analysis was performed.
Real time reverse transcriptase-polymerase 
chain reaction (RT-PCR)
Real-time RT-PCR analyses were performed 
using the ABI Prism 7000 Sequence detection 
system (Applied Biosystems, Foster City, CA). The 
standard reaction volume was 20 μL and the PCR 
kit used was Go Green Master Mix-Taq (Promega, 
Madison), 5.0 μL of cDNA template, and 4 μM 
of both forward and reverse primers. The initial 
step of PCR was pre-heated at approximately 
95 °C for 3 minutes; denaturated for 39 cycles 
at 95 °C for 30 seconds, annealed at 55 °C for 1 
minute, and extended at 72 °C for 1 minute with 
additional final extension at 72 °C for 10 minutes. 
The p53 fragment was 741 base pairs (bp). 
Glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH) was used for normalization. The p53 
fragment was isolated using 5’AGA GTC TAT AGG 
CCC ACC CC3’  forward primer and 5’GCT CGA 
CGC TAG GAT CTG AC3’ reverse primer following 
the reseach of Ohtani.8 The Bcl2 fragment was 
isolated using 5’GAC AGA AGA TCA TGC CGT CC3’ 
forward primer and 5’GGT ACC AAT GGC ACT 
TCA AG3’, the Bcl2 fragment was 76 bp, reverse 
primer based on the research by Mbazima.9 
The FasL fragment was isolated using  5’GCA 
GCC CTT CAA TTA CCC AT3’ forward primer and 
5’CAG AGG TTG GAC AGG GAA GAA3’, the FasL 
fragment was 101 bp, reverse primer based on 
the research by Das.10
Data analysis
The statistical analyses used were Shapiro-Wilk 
test, independent t test, Chi-square test, ANOVA 
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test, Pearson’s correlation and the regression 
test (which is used to compare two groups of 
subjects or bivariate) as well as the multiple 
logistic regression test (multivariate). The data 
analysis was performed using SPSS ver. 13.0 at a 
95% confidence interval (p≤0.05).
Results 
Identification of preeclamptic subjects (n=31) 
were made based on preeclampsia clinical 
diagnosis which includes the presence of 
hypertension (>140/90 mmHg). Normortensive 
pregnant women were included as the control 
subjects (n=31). The main clinical parameters 
include gestational age, body mass index, age, 
and parity (Table 1). During the period of July 
2009 and April 2010, a continuous series of 31 
preeclamptic patients were studied.
No significant differences were found between 
the preeclamptic and normal pregnancies in 
terms of gestational age, BMI, maternal age, and 
parity (Table 1). Therefore, the characteristics of 
both groups can be considered homogeneous 
and the results of subsequent examinations can 
be considered as comparable.  
Based on the Chi-square test, a significant 
correlation was seen between the incidence of 
preeclampsia and VCAM-1(p=0.001), p53 mRNA 
expression (p=0.010) and Bcl2 mRNA (p=0.041), 
whereas the FasL mRNA expression showed no 
significant relationship with the incidence of 
preeclampsia (p=0.300) (Table 2). Multivariable 
tests were performed on variables that had a 
value of p<0.25 (Table 3).
Multiple logistic regression analysis showed 
that the most dominant molecule associated 
with the incidence of preeclampsia was VCAM-
1 (OR=16.77), which indicates that the levels of 
VCAM-1 are not normal, showing a 17-fold higher 
incidence risk for preeclampsia than the normal 
levels of VCAM-1. This result shows that VCAM-
1 is the most dominant risk factor in predicting 
the incidence of preeclampsia (p<0.001). For the 
preeclamptic group, there was a significantly 
negative correlation between the levels of 
p53 and VCAM-1 (p=0.005 and r=0.490) which 
indicates a weak association. For the normal 
pregnancy group, there was a significantly 
negative correlation between p53 and higher 
levels of VCAM-1 (p=0.0200 and r=0.415), 
indicating a weak association. There was a 
negative but statistically insignificant correlation 
between the levels of Bcl2 and VCAM-1 (p=0.093 
and r=0.619) in the preeclamptic group, 
indicating that the power of the correlation is 
weak. For the normal pregnancy group, there 
was a negative correlation between the levels of 
Bcl2 and VCAM-1, but this correlation was not 
statistically significant (p=0.278 and r=0.201), 
indicating that the correlation is very weak 
(Table 4). The correlation between the levels of 
Bcl2/p53 ratio and VCAM-1 in the preeclamptic 
group was significantly positive (p=0.002 and 
r=0.541) which indicates a weak relationship. 
In the normal pregnancy group, there was no 
significant positive correlation (p=0.595 and 
r=0.099), indicating that the strength of the 
correlation is very weak (Table 5).
Discussion
The symptoms of hypertension associated with 
preeclampsia is developed during pregnancy and 
disappear after birth. This condition suggested 
that the placenta plays an important role as 
a source of preeclampsia. There is growing 
evidence for the notion that the dysfunction 
of endothelial cells is the major contributor to 
preeclampsia. Although the mechanism of the 
activation of endothelial dysfunction is already 
well understood, there is evidence suggesting that 
leukocytes play a role in this destructive process. 
Endothelial dysfunction leads to increased levels 
of VCAM-1 in the blood or urine of women with 
preeclampsia several weeks before and during 
pregnancy. The mean levels of VCAM-1 in the 
preeclampsia group were higher (1,077.63 ng/
mL) than the controls (823.99 ng/mL), (p=0.006). 
VCAM-1 indicates the presence of inflammation 
in preeclampsia. The inflammation results from 
endothelial damage; therefore, VCAM-1 is a 
marker of endothelial damage.11 In our study, 
medium levels of VCAM-1 (>890.08 ng/mL) were 
not significantly associated with preeclampsia 
(p=0.401). This result is understandable because 
there are many factors that trigger preeclampsia 
other than the endothelial damage. One of the 
factors that allegedly contribute to triggering the 
onset of preeclampsia is apoptosis as a result of 
placental hypoxia leading to placental ischemia.
Our study indicated that the levels of VCAM-1 
were high (>890.08 ng/mL) in 23 preeclampsia 
individuals (74.2%), compared to only 10 in the 
control group (32.3%), whereas  8 individuals 
(25.8%) of  the preeclampsia case group and 
21 individuals of the control group (67.7%) 
showed low levels of VCAM-1 (<890.08 ng/mL). 
This result is consistent with the theory that 
placental ischemia plays a role in preeclampsia 
syndrome; whereas in preeclampsia, increased 
adhesion molecule expression in the maternal 
circulation and elevated levels of homocysteine 
are found. Elevated level of VCAM-1 is one of the 
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characteristics of the endothelial dysfunction, 
resulting in a lack of uteroplacental perfusion. 
Uteroplacental insufficiency leads to the release 
of free radicals and induces hypoxia. Hypoxia is 
thought to cause the increased phosphorylation 
of p53 if there is an increased metabolic process 
at the level of the p53 gene and reduces the 
role of MDM-2, which will ultimately enhance 
the role of p53 in the apoptotic process. The 
relationship between p53 mRNA expression and 
the incidence of preeclampsia was significant 
(p=0.010, Table 2). These results are consistent 
with in vitro and in vivo models.6,12 The p53 gene 
protects cells against DNA damage and plays a 
role in DNA repair. The loss or inactivation of 
p53 would result in the disruption of genetic 
equilibrium. 
The relation between the level of Bcl2 mRNA 
expression and the incidence of preeclampsia 
(Table 2) in this study was significant (p=0.041). 
This result is consistent with the theory that the 
pathway that is more involved in the hypoxic 
conditions in preeclampsia is the more dominant 
intrinsic pathway in which the expression of 
Bcl2 decreased to induce apoptosis. It has been 
hypothesized that hypoxia would cause the loss 
of Bcl2 and/or Bcl-XL from the mitochondrial 
membrane and these proteins would be replaced 
by proapoptotic proteins, such as Bak, Bax and 
Bim. Our results on Bcl2 are in agreement with 
the results from previous reports.13,14
The FasL/Fas pathway is one of the body’s 
main pathways to control placental apoptosis. 
Extrinsic pathways are thought to be the 
pathogenesis of preeclampsia. As reported by 
Laskowska15, when apoptosis occurred in normal 
pregnancy, a more advanced stage of pregnancy 
was associated with a higher rate of apoptosis 
in placentas. In preeclamptic pregnancies, CD4+ 
T cells produce more Th1 cytokines, such as 
IL2, IFNα and TNFβ, which induce an increase 
in apoptosis. This result was shown by Zou et 
al.16 who showed that a large concentration of 
IFNα induced the increased expression of FasL/
Fas.16 The results of the multivariable analysis 
of the relationship between risk factors (Table 
3). The mRNA expression levels of p53 and 
Bcl2 and VCAM-1 levels were associated with 
preeclampsia, and VCAM-1 was the primary risk 
factor in predicting the incidence of preeclampsia 
(p< 0.001).
The results of this study showed a significant 
negative correlation between the expression 
of p53 mRNA and VCAM-1 levels in both the 
preeclampsia and normal pregnancy groups. The 
possible absence of correlation between VCAM-
1 and p53 may be due to many other factors 
that cause endothelial dysfunction in addition 
to VCAM-1, such as LDL, ICAM1, PECAM1 and 
von Willebrand factor VIII. It was reported on 
a study that a significant increase in ICAM1 
expression but not VCAM-1 expression was 
found in preeclampsia. This result is in contrast 
with reports by Ohtani et al.8 who showed that 
ICAM1, VCAM-1, E-selectin and PECAM1 levels 
were significantly elevated in preeclampsia. It 
is possible that these results could explain the 
negative correlation between the expression of 
p53 and Bcl2 mRNA with VCAM-1 levels. 
In summary, these results indicate a positive 
weak correlation between the Bcl2/p53 ratio 
and higher levels of VCAM-1 in the preeclamptic 
group. In the normal pregnancy group, there is a 
very weak positive correlation between the Bcl2/
p53 ratio and higher levels of VCAM-1. These 
results show that increases in the Bcl2/p53 ratio 
will be followed by elevated levels of VCAM-
1 in preeclampsia, in which the expression of 
p53 would affect the balance of Bcl2 and Bax, 
as an intrinsic pathway of apoptosis in the 
mitochondrial membrane and the occurrence 
of placental apoptosis resulting in hypoxia. 
Hypoxia will increase the levels of free radicals 
that cause damage to endothelial cells which is 
characterized by increased levels of VCAM-1.
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